Erasca Inc(ERAS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.95 | Insider Own | 29.33% | Shs Outstand | 312.6M | Perf Week | 4.35% |
| Market Cap | 5.29B | Forward P/E | - | EPS next Y | 36.24% | Insider Trans | - | Shs Float | 247.2M | Perf Month | 6.4% |
| Enterprise Value | 5.06B | PEG | - | EPS next Q | -0.13 | Inst Own | 61.84% | Short Float | 14.95% | Perf Quarter | -19.06% |
| Income | -0.29B | P/S | - | EPS this Y | -121.2% | Inst Trans | 3.06% | Short Ratio | 8.39 | Perf Half Y | 65.97% |
| Sales | 0.00B | P/B | 13.06 | EPS next 5Y | -20.83% | ROA | -65.25% | Short Interest | 36.96M | Perf YTD | 306.45% |
| Book/sh | 1.16 | P/C | 19.68 | EPS past 3/5Y | 39.56% 12.46% | ROE | -78.25% | 52W High | -37.73% ($24.28) | Perf Year | 519.67% |
| Cash/sh | 0.77 | P/FCF | - | Sales past 3/5Y | - | ROIC | -71.6% | 52W Low | 618.29% ($2.11) | Perf 3Y | 659.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -110.63% | Gross Margin | - | Volatility(W/M) | 5.63% 6.86% | Perf 5Y | -19.92% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.98 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.29 | EPS Q/Q | -18.39% | Profit Margin | - | RSI (14) | 51.82 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.29 | Sales Q/Q | - | SMA20 | 2.98% ($14.68) | Beta | 0.69 | Target Price | $23.7 |
| Payout | - | Debt/Eq | 0.12 | Earnings | 2026/8/11 | SMA50 | -3.08% ($15.6) | Rel Volume | 0.77 | Prev Close | $15.22 |
| Employees | 103 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -25.67% - | SMA200 | 1.24% ($14.93) | Avg Volume(3M) | 4.41M | Price | $15.12 |
| IPO | 2021/7/16 | Option/Short | Yes/Yes | Trades | 23800 | Volume | 3,385,889 | Change | -0.66% |
A clinical-stage biotech company developing oncology drugs. It is developing anti-cancer candidates that target the RAS signaling pathway, which drives cancer, and is conducting clinical trials across a range of solid tumor indications. The company is a biotech firm specialized in RAS-targeted anti-cancer drugs.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
ERAS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -121.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -19.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 61.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #50 of 594 in the industry
Based on market cap of $5B.
FAQ
What kind of company is ERAS?
ERAS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ERAS?
The market cap of ERAS is approximately $5.3B, ranking 1,335 within its sector.
What is the 52-week high and low for ERAS?
ERAS has recorded a 52-week high of $24.28 and a low of $2.11.
